{"nctId":"NCT00738062","briefTitle":"Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)","startDateStruct":{"date":"2008-01"},"conditions":["Neurogenic Orthostatic Hypotension","Non-Diabetic Autonomic Neuropathy","Multiple System Atrophy","Dopamine Beta Hydroxylase Deficiency"],"count":103,"armGroups":[{"label":"Droxidopa","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Droxidopa"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Droxidopa","otherNames":[]},{"name":"Placebo","otherNames":["Inactive drug (to look like Droxidopa)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nTo be eligible for inclusion, each patient must fulfill the following criteria:\n\n* Participated in Droxidopa Protocol 302;\n* Provide written informed consent to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical care.\n\nExclusion Criteria:\n\nPatients are not eligible for this study if they fulfill one or more of the following criteria:\n\n* Currently taking ephedrine or midodrine;\n* Patients taking ephedrine or midodrine must stop taking these drugs at least 2 days prior to their study entry visit (Visit 1).\n* Currently taking anti-hypertensive medication;\n\n  \\* The use of short-acting anti-hypertensive medications at bedtime is permitted.\n* Currently taking tri-cyclic antidepressant medication or other norepinephrine re-uptake inhibitors;\n* Have changed dose, frequency and or type of prescribed medication, within two weeks of study start (excluding ephedrine and midodrine);\n* History of more than moderate alcohol consumption;\n* History of known or suspected drug or substance abuse;\n* Women of childbearing potential who are not using a medically accepted contraception;\n\n  * Reproductive potential:\n  * Female subjects should be either post-menopausal (amenorrhea for at least 12 consecutive months), surgically sterile, or women of child-bearing potential (WOCP) who are using or agree to use acceptable methods of contraception.\n  * Acceptable contraceptives include intrauterine devices (IUDs), hormonal contraceptives (oral, depot, patch or injectable) and double barrier methods such as condoms or diaphragms with spermicidal gel or foam.\n  * For WOCP a urine pregnancy test must be conducted at each study visit.\n  * WOCP must be advised to use acceptable contraceptives throughout the study period and for 30 days after the last dose of investigational product.\n  * If hormonal contraceptives are used they should be taken according to the package insert.\n  * WOCP who are not currently sexually active must agree to use acceptable contraception, as defined above, if they decide to become sexually active during the period of the study and for 30 days after the last dose of investigational product.\n* Sexually active males whose partner is a WOCP and who do not agree to use condoms for the duration of the study and for 30 days after the last dose;\n* Women who are pregnant or breast feeding;\n* Known or suspected hypersensitivity to the study medication or any of its ingredients;\n* Pre-existing sustained severe hypertension (BP 180/110 mmHg in the sitting position);\n* Have atrial fibrillation or, in the investigator's opinion, have any other significant cardiac arrhythmia;\n* Any other significant systemic, hepatic, cardiac or renal illness;\n* Diabetes mellitus or insipidus;\n* Have a history of closed angle glaucoma;\n* Have a known or suspected malignancy;\n* Have a serum creatinine level \\> 130 umol/L;\n* Patients with known gastrointestinal illness or other gastrointestinal disorder that may, in the investigator's opinion, affect the absorption of study drug;\n* In the investigator's opinion, have clinically significant abnormalities on clinical examination or laboratory testing;\n* In the investigator's opinion, are unable to adequately co-operate because of individual or family situation;\n* In the investigator's opinion, are suffering from a mental disorder that interferes with the diagnosis and/or with the conduct of the study, e.g. schizophrenia, major depression, dementia;\n* Are not able or willing to comply with the study requirements for the duration of the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Orthostatic Hypotension Questionnaire Composite Score (OHQ)","description":"The OHQ is the average of two sub-scales, the Orthostatic Hypotension Symptom Assessment Scale (OHSA) and the Orthostatic Hypotension Daily Activities Scale (OHDAS). Each asks the patient to rate their symptoms or disease impact over the past week. The OHSA sub-scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. The OHDAS sub-scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.\n\nIn this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug). All patients are on open-label droxidopa for 3 months prior to randomization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.57","spread":"1.891"},{"groupId":"OG001","value":"0.90","spread":"1.550"}]}]}]},{"type":"SECONDARY","title":"Change in Orthostatic Hypotension Daily Activities (OHDAS) Score","description":"The OHDAS scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each asks the patient to rate their disease impact over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.\n\nChange: score at end of randomization minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.53","spread":"2.204"},{"groupId":"OG001","value":"0.71","spread":"1.629"}]}]}]},{"type":"SECONDARY","title":"Change in Orthostatic Hypotension Symptom Assessment (OHSA) Composite Score","description":"The OHSA scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. Each asks the patient to rate their symptoms over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.\n\nChange: score at end of randomization minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.59","spread":"1.963"},{"groupId":"OG001","value":"1.10","spread":"1.658"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure (SBP) Measurements 3 Minutes Post Standing","description":"Change: standing systolic blood pressure at end of study minus standing systolic blood pressure at randomization. In this withdrawal design, a negative score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug). All patients are on open-label droxidopa for 3 months prior to randomization to either continued droxidopa or to placebo.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.4","spread":"26.63"},{"groupId":"OG001","value":"0.0","spread":"18.51"}]}]}]},{"type":"POST_HOC","title":"Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1)","description":"OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug). All patients were on open-label droxidopa for 3 months prior to randomization to either continued droxidopa or to placebo.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"2.39"},{"groupId":"OG001","value":"1.3","spread":"2.21"}]}]}]},{"type":"SECONDARY","title":"Patient Reported Clinical Global Impression - Severity","description":"The CGI-S is a 7 point scale ranging from a score of 1 (no symptoms) to 7 (severe symptoms). Patients were grouped according to OH severity at the end of the randomization period as follows;\n\n* Normal-Borderline OH (CGI-S 1-2),\n* Mild-Moderate OH (CGI-S 3-4),\n* Marked OH-Most Ill with OH (CGI-S 5-7). .","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinician Recorded Clinical Global Impression - Severity","description":"The CGI-S is a 7 point scale ranging from a score of 1 (no symptoms) to 7 (severe symptoms). Patients were grouped according to OH severity at the end of the randomization period as follows;\n\n* Normal-Borderline OH (CGI-S 1-2),\n* Mild-Moderate OH (CGI-S 3-4),\n* Marked OH-Most Ill with OH (CGI-S 5-7).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient Reported Clinical Global Impression - Improvement","description":"The CGI-I is a 7 point scale ranging from a score of 1 (very much improved) to 7 (very much worse), with no change in the middle, and assesses the improvement in relation to the baseline evaluation.\n\nPatients will be grouped according change in disease as follows;\n\n* Very Much Improved to Slightly Improved (CGI-I 1-3),\n* No Change (CGI-I 4),\n* Slightly Worse to Very Much Worse (CGI-I 5-7).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinician Rated Clinical Global Impressions - Improvement","description":"The CGI-I is a 7 point scale ranging from a score of 1 (very much improved) to 7 (very much worse), with no change in the middle, and assesses the improvement in relation to the baseline evaluation.\n\nPatients will be grouped according change in disease as follows;\n\n* Very Much Improved to Slightly Improved (CGI-I 1-3),\n* No Change (CGI-I 4),\n* Slightly Worse to Very Much Worse (CGI-I 5-7).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":102},"commonTop":["Fall","Urinary Tract Infection","Headache","Back pain","Syncope"]}}}